An enzyme immunoassay for plasma betamethasone

Area of Science:

• Biochemistry
• Analytical Chemistry
• Pharmacology

Background:

• Plasma betamethasone measurement is crucial for therapeutic drug monitoring.
• Existing radioimmunoassay (RIA) methods have limitations in sensitivity and require radioactive isotopes.
• Development of a highly sensitive and non-radioactive assay is desirable.

Purpose of the Study:

• To develop and characterize a sensitive enzyme immunoassay (EIA) for quantifying plasma betamethasone.
• To compare the performance of the developed EIA with a conventional radioimmunoassay (RIA).

Main Methods:

• A novel enzyme immunoassay was established using a betamethasone conjugate and a fluorescence substrate.
• The assay employed betamethasone-3-(O-carboxymethyl)oxime-beta-D-galactosidase as the labeled antigen.
• Performance metrics including sensitivity, specificity, and precision were evaluated and compared to RIA.

Main Results:

• The developed EIA demonstrated a minimal detectable level of 0.15 pg/tube (0.15 ng/ml), significantly exceeding the RIA's sensitivity (10 pg/tube or 2 ng/ml).
• The assay exhibited sufficient specificity, with a low cross-reactivity of 0.008% for cortisol.
• However, the precision of the EIA was found to be inferior to that of the RIA.

Conclusions:

• The developed enzyme immunoassay provides a highly sensitive and specific method for plasma betamethasone determination.
• While sensitivity is improved, further optimization may be needed to match the precision of radioimmunoassay.
• This EIA offers a promising non-radioactive alternative for clinical and research applications.